Pictet Asset Management (Switzerland)’s Myriad Genetics MYGN Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$25.4M	Buy	1,095,566 +222,228	+25%	+$4.85M	0.03%	410
2023 Q1	$20.3M	Buy	873,338 +572,778	+191%	+$11.6M	0.03%	458
2022 Q4	$4.36M	Buy	300,560 +78,881	+36%	+$1.47M	0.01%	766
2022 Q3	$4.23M	Buy	221,679 +48,269	+28%	+$1.11M	0.01%	771
2022 Q2	$3.15M	Buy	173,410 +10,615	+7%	+$220K	﹤0.01%	861
2022 Q1	$4.1M	Sell	162,795 -3,939	-2%	-$101K	﹤0.01%	849
2021 Q4	$4.6M	Sell	166,734 -34,642	-17%	-$1M	﹤0.01%	853
2021 Q3	$6.5M	Buy	+201,376	New	+$6.69M	0.01%	788

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s MYGN Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Myriad Genetics (MYGN) stake by 25% in Q2 2023, buying an estimated $4.85M and bringing the position to 1,095,566 shares worth $25.4M. The position accounts for 0.03% of the portfolio, ranked #410.

Pictet Asset Management (Switzerland) first reported a position in MYGN in Q3 2021 and has held it in 8 quarters since. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,095,566 shares of Myriad Genetics worth $25.4M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 222,228 Myriad Genetics shares in Q2 2023, an estimated $4.85M.
Myriad Genetics made up 0.03% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #410 holding.
Pictet Asset Management (Switzerland) first reported a position in Myriad Genetics in Q3 2021 and has held it in 8 quarters since.
188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.